Loading…
No business profile yet.
Size Grape King Bio (1707.TW) is a Taiwan Health Care company (Pharmaceuticals: Other) with a market value of $361M, the 566th largest of 687 Taiwan companies the cockpit tracks. Shares closed at NT$80.50 on 6 Nov 2026.
Performance Over six months the shares fell 28.4%, against -21.2% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 5th lowest of 21 in its peer set.
Growth Revenue fell 6.9% over the last twelve months (peer median -2.1%); the operating margin is 20.1% (peer median 10.8%).
Valuation It trades at 11.0× forward earnings against a peer median of 16.9× (4th cheapest of 8).
Price implies For today's price to make sense, revenue must grow about -19% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is -21 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 12.2 points above its cost of capital (5.0% WACC).
Next results Next results expected around 11 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | NT$10.1B | NT$10.3B | NT$11.2B | NT$10.6B | NT$10.4B |
| Revenue growth | — | -8% | +5% | +2% | — |
| Gross profit | NT$7.18B | NT$7.44B | NT$8.42B | NT$8.31B | NT$8.27B |
| EBITDA | NT$2.59B | NT$2.69B | NT$3.01B | NT$2.95B | NT$3.00B |
| Net income | NT$1.15B | NT$1.22B | NT$1.45B | NT$1.45B | NT$1.46B |
| Free cash flow | NT$1.50B | NT$1.73B | NT$1.25B | NT$1.93B | NT$2.50B |
| Capital expenditure | NT$514M | NT$464M | NT$648M | NT$602M | NT$502M |
| Total debt | NT$187M | NT$215M | NT$161M | NT$193M | NT$158M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 1707.TW | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -4.8% | -9.1% | 6th highest of 21 |
| 6-month return | -28.4% | -21.2% | 5th lowest of 21 |
| Distance from 52-week high | -38.1% | -38.8% | 10th highest of 21 |
| Revenue growth (TTM) | -6.9% | -2.1% | 7th lowest of 19 |
| Operating margin | 20.1% | 10.8% | 6th highest of 20 |
| Forward P/E | 11.0× | 16.9× | 4th cheapest of 8 |
| Growth the price implies (Req g, 7 yrs) | -18.9% | 2.4% | least demanding of 15 |
| Growth delivered (Del g) | +2.3% | +6.5% | 6th lowest of 14 |
| Hurdle (Req g minus delivered) | -21.1 pp | -0.9 pp | 2nd least demanding of 14 |
| ROIC minus cost of capital | +12.2 pp | -0.2 pp | 5th highest of 19 |
| EV / EBITDA | 3.8× | 10.9× | cheapest of 5 |
| Net debt / EBITDA | -1.4× | -3.4× | 3rd most indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Grape King Bio 1707.TW | Taiwan | $361M | -28% | -7% | 20% | 11.0× | -18.9% | +2.3% |
| Daiken Biomedical 7780.TW | Taiwan | $352M | -24% | n/a | 18% | n/a | 0.3% | n/a |
| Zhejiang Xinguang Pharmaceutical 300519.SZ | China | $349M | -11% | +5% | 27% | n/a | 5.2% | -1.3% |
| Boiron BOI.PA | France | $391M | -31% | -2% | 5% | 9.7× | -0.3% | -0.5% |
| TCI 8436.TWO | Taiwan | $320M | -24% | -2% | 18% | 10.0× | -13.0% | -3.2% |
| Weihai Baihe Biology Technological 603102.SS | China | $314M | -20% | +18% | 14% | 17.6× | -10.2% | +9.6% |
| Tibet Aim Pharm 002826.SZ | China | $427M | -23% | +13% | 14% | n/a | 1.3% | +1.0% |
| Myung in Pharm 317450.KS | South Korea | $455M | -24% | +7% | 35% | n/a | -14.7% | +8.9% |
| Lionco Pharmaceutical 603669.SS | China | $581M | +21% | -6% | -17% | n/a | n/a | n/a |
| Hunan Hansen Pharmaceutical 002412.SZ | China | $582M | +10% | -4% | 21% | n/a | 3.0% | +7.0% |
| Lanzhou Foci Pharmaceutical 002644.SZ | China | $582M | -9% | +3% | 5% | n/a | 24.3% | +6.5% |
| Hangzhou Minsheng Healthcare 301507.SZ | China | $624M | -21% | +21% | 11% | 48.6× | 20.4% | +12.1% |
| ABA Chemicals 300261.SZ | China | $641M | -27% | -16% | -23% | 438.0× | n/a | n/a |
| CK Life Sciences International (Holdings) 0775.HK | Hong Kong | $644M | -30% | 0% | 0% | n/a | n/a | n/a |
| ArriVent BioPharma AVBP | United States | $673M | -54% | n/a | n/a | n/a | n/a | n/a |
| Shanxi Zhendong Pharmaceutical 300158.SZ | China | $713M | -16% | -28% | -25% | n/a | n/a | n/a |
| Brother Enterprises 002562.SZ | China | $716M | -28% | +8% | 4% | n/a | 4.9% | +13.5% |
| China Shineway Pharmaceutical 2877.HK | Hong Kong | $719M | -21% | -18% | 25% | 7.2× | n/a | n/a |
| Shanghai Kaibao Pharmaceutical 300039.SZ | China | $756M | -17% | -14% | 22% | n/a | 1.8% | +4.8% |
| Sirio Pharma 300791.SZ | China | $790M | -12% | -9% | 1% | 16.9× | 14.7% | +15.6% |
| Tianjin Tianyao Pharmaceuticals 600488.SS | China | $801M | -14% | -12% | 3% | n/a | 3.6% | -1.3% |